T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
GlobalData on MSN11h
MSD wins FDA priority review for Welireg in rare endocrine cancerThe US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to ...
The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...
The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...
The FDA has approved Grafapex (treosulfan) for use in combination with fludarabine as a preparative regimen for allogeneic HSCT in patients aged 1 year and older with AML or MDS.
After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback